Selegiline Enhances Cell Viability in Neural Stem/Progenitor Cells
In vitro studies showed that selegiline significantly improved the viability of HD-NSC (hippocampal-derived neural stem/progenitor cells), decreased apoptotic and necrotic cell fractions, and increased the expression of key protective genes (PGC-1α, Nrf2, Bcl-2) compared to untreated cells.
- Tags
- #MSResearch
- Most relevant to
- —
Why it matters
These findings suggest that selegiline could protect neural stem cells from oxidative stress, highlighting its potential role in neuroprotection.
What this does not prove
The study used only in vitro models which may not fully capture the complexities of human multiple sclerosis pathology. It did not assess effects in living organisms or clinical settings.
Next milestone
No next milestone was established from the available source.
Study facts
- Study design
- Not reported
- Participants / samples
- Not reported
- Randomised
- Not reported
- Controlled
- Not reported
- Primary endpoint met
- Not reported
- Relevant MS type
- Not reported
- Publication date
- 2026-05-31
- Evidence reviewed
- Abstract only
- Regulatory approval
- Not reported
- Research areas
- Not classified
Original sources
- Primary evidenceSelegiline induces neuroprotection via PGC-1α/Nrf2 gene upregulation in H2O2 -treated hippocampal-derived neural stem/progenitor cells. ↗DOI: 10.14715/cmb/2026.72.5.7
Supporting passages (6)
peer reviewedNo
publication date2026-05-31
interventionSelegiline
primary endpointCell viability
findingsTreatment with 10⁻⁷ M selegiline significantly enhanced HD-NSC viability, reduced apoptotic and necrotic cell fractions, and upregulated PGC-1α, Nrf2, and Bcl-2 expression compared to untreated cells (P < 0.05).
limitationsTitle: Selegiline induces neuroprotection via PGC-1α/Nrf2 gene upregulation in H2O2 -treated hippocampal-derived neural stem/progenitor cells.
AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.